This article is more than 5 years old. Information may no longer be current.
Aflibercept may minimize treatment burden in patients with CRVO
Click Here to Manage Email Alerts
CHICAGO — The cystoid macular edema-free interval in patients with non-ischemic central retinal vein occlusion previously treated with ranibizumab or bevacizumab is increased with use of aflibercept, according to a speaker here.
Presenting the initial results of the Newton trial, Rahul N. Khurana, MD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting that switching to Eylea (aflibercept, Regeneron) may increase the treatment interval in patients with this disease.
Rahul N. Khurana
The Newton trial is a phase 4, prospective, single-arm, interventional study being conducted at a single center. In the interim analysis of 14 patients with at least 6 months of follow-up, the primary endpoint of cystoid macular edema-free interval was increased from 39 to 62 days, which was statistically significant (P = .0001), according to Khurana.
“We showed that aflibercept extends the interval by 22 days. What does an extra 3 weeks mean clinically?” Khurana asked.
Before switching to aflibercept, patients would require approximately nine visits and injections in the course of a year. After initiating aflibercept treatment, however, patients would need only 5.5 visits and injections per year, according to Khurana.
Disclosure: Khurana has financial relationships with Allergan, Genentech and Regeneron. The Newton study is supported through an investigator-initiated study funded by Regeneron.